“I think the election will be a huge catalyst,” Lopez said on Wednesday. He was busy planning for the initial public offering (IPO) with investment banking firm Boustead Securities set to be the company’s chief adviser.
Lopez is far from alone. U.S.-based dispensary business Gage Cannabis announced two weeks ago it would seek to list in the new year, while synthetic cannabinoid maker BioMedican has also laid out plans to go public in the first half of 2021.
Today’s outlook is a far cry from 2018, when many Canadian-based players created for last year’s legalization there, as well as expectations of the widespread opening of U.S. markets, faced fines and shutdowns, or were forced to merge, due to regulatory roadblocks that hampered growth prospects.
Lopez and other CEOs say the potential January arrival in the White House of Democratic presidential candidate Joe Biden and his pro-decriminalization running-mate, Senator Kamala Harris, may prove a watershed moment for the industry.
‘DRAMATIC CHANGE IN EXPECTATIONS’
Shares of companies with broad footprints in the U.S. market, including Curaleaf Holdings Inc, Cresco Labs Ltd and Green Thumb Industries Inc are all up more than 20% since the presidential debate on Sept. 29, mirroring rising expectations of a Biden victory.
“Each election cycle cannabis comes closer to federal acceptance, and this election is pivotal to those goals,” said Cynthia Salarizadeh, founder and president of House of Saka, a cannabis-infused beverages business.
A Democratic victory for control of the Senate, which is looking increasingly likely according to polls, would replace Republican Majority Leader Mitch McConnell, who has blocked legislation that would allow cannabis companies greater access to financial markets.
Cannabis sales have surged with people stuck at home during the coronavirus pandemic. In California, sales data for August showed a 26% jump over the past year, while sales in Nevada were up 34%, according to BDS Analytics.
Many point to Canada as an example.
Though the country became the first G-20 nation to legalize recreational use of cannabis in 2018, regulatory hiccups in Canadian dispensary rollouts, slow international legalization and a lack of profitability sent investors packing over the next year. That left most companies at a fraction of their market values by the beginning of this year.
Michael Underhill, chief investment officer at Capital Innovations, cautioned that several bills would need to pass before U.S. companies will be on the same regulatory playing field as their Canadian counterparts.
(Reporting by Shariq Khan and David Randall; Editing by Patrick Graham, Ira Iosebashvili and Bill Berkrot)
For more information on Hempsmart CBD Product Line
Steven Smith, CEO Owner/Founder
Background Noise Studios